William B Stallcup

US Patent:

6528481, Mar 4, 2003

Filed:

Feb 16, 1999

Appl. No.:

09/250700

Inventors:

Michael A. Burg - San Diego CA
Renata Pasqualini - Solana Beach CA
Wadih Arap - Solana Beach CA
Erkki Ruoslahti - Rancho Santa Fe CA
William B. Stallcup - Del Mar CA

Assignee:

The Burnam Institute - La Jolla CA

International Classification:

A01N 3718

US Classification:

514 2, 514 4, 514 15, 530300, 530305, 530328, 530395, 536 231, 536 235, 424 932, 4241851, 4241931

Abstract:

The present invention provides angiogenic vasculature homing molecules that bind to NG2/HM proteoglycan, including, for example, a peptide comprising the amino acid sequence TAASGVRSMH (SEQ ID NO:1) or LTLRWVGLMS (SEQ ID NO:2). The invention also provides conjugates comprising an angiogenic vasculature homing molecule linked to a moiety such as a drug, a cytotoxic agent, a chemotherapeutic agent, or a detectable agent. The invention additionally provides a method of targeting angiogenic vasculature in a tumor in vivo by contacting the angiogenic vasculature with an angiogenic vasculature homing molecule that selectively homes to a NG2/HM proteoglycan, wherein the angiogenic vasculature homing molecule is not an antibody. The invention additionally provides a method of inhibiting angiogenesis in a tumor of a subject by administering to the subject a conjugate comprising a moiety linked to an angiogenic vasculature homing molecule that selectively binds a NG2/HM proteoglycan, wherein the angiogenic vasculature homing molecule is not an antibody.